Study Shows Efficacy of Selpercatinib in RET Fusion–Positive NSCLC
On August 27, 2020, the manufacturer announced phase l/ll study results of the registrational trial for selpercatinib, the first and only therapy indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Selpercatinib is a novel, ATP-competitive, highly selective small-molecule inhibitor of RET kinase. Selpercatinib was designed to penetrate the central nervous system. Read more. |
FDA Grants Priority Review of Trilaciclib for Treating Small Cell Lung Cancer The FDA accepted a New Drug Application for trilaciclib for small cell lung cancer patients being treated with chemotherapy. Trilaciclib is a first-in-class investigational therapy intended to preserve bone marrow and immune system function during chemotherapy and enhance patient outcomes. In 2019, trilaciclib received an FDA Breakthrough Therapy Designation. Read more.
|